Using mobile technology to manage high blood pressure
A Two-arm Parallel Randomized Clinical Trial of Implementation of Technology-enabled Management Versus Usual Care for Blood Pressure
NA · Stanford University · NCT05479461
This study is testing if using a mobile app to manage high blood pressure works better than regular doctor visits for patients who might change their blood pressure medications.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 30 Years to 90 Years |
| Sex | All |
| Sponsor | Stanford University (other) |
| Locations | 3 sites (Palo Alto, California and 2 other locations) |
| Trial ID | NCT05479461 on ClinicalTrials.gov |
What this trial studies
This clinical trial compares the effectiveness of a digital hypertension management system with usual care for patients with high blood pressure. Participants will be randomly assigned to either receive the mobile technology intervention or standard care from their healthcare providers. The study aims to enroll at least 200 patients, with 100 in each group, to evaluate how well the digital system helps in managing blood pressure levels. The trial focuses on patients who can potentially adjust their hypertension medications under the guidance of their clinicians.
Who should consider this trial
Good fit: Ideal candidates are adults aged 30-90 with high blood pressure who own a smartphone and can adjust their hypertension medications.
Not a fit: Patients with severe heart conditions, recent cardiovascular events, or those currently enrolled in other studies may not benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could lead to better blood pressure control and improved cardiovascular health for patients.
How similar studies have performed: Other studies have shown promising results using digital health technologies for managing hypertension, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 30-90 yrs. * Smartphone ownership * Office SBP: ≥ 140 mm Hg * ≤ 2 current anti-HTN meds * Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose) * English or Spanish-speakers Exclusion Criteria: * Heart failure with reduced ejection fraction (EF \< 40%) * ESRD (GFR \<15) * Renal replacement therapy * Pregnant * Myocardial infarction or stroke within preceding 6 months * Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months * Prior solid organ transplantation * At the clinical discretion of the investigators * Enrolled in another clinical study
Where this trial is running
Palo Alto, California and 2 other locations
- Stanford Health Care — Palo Alto, California, United States (RECRUITING)
- Morehouse School of Medicine — Atlanta, Georgia, United States (RECRUITING)
- Lake Country Medical Group — Eatonton, Georgia, United States (RECRUITING)
Study contacts
- Principal investigator: Paul J Wang, MD — Stanford University
- Study coordinator: Paul J Wang, MD
- Email: pjwang@stanford.edu
- Phone: (650) 723-9363
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hypertension, High blood pressure, Digital Health Mobile Technology, Cardiovascular risk, Clinical Research, Medications